Key Ideas

Medical eligibility for CAR T-cell therapy or bispecific antibodies is necessary but not sufficient. Distance to a treatment center, caregiver availability, lodging, and insurance network status often determine whether a medically appropriate option is actually delivered. Real-world data show a meaningful share of referred patients never reach CAR T-cell therapy for a range of reasons, including disease progression and logistical barriers. Response rates reported among treated patients do not capture those who never reach treatment. [1]

A Tale of Two Patients with the Same Diagnosis

Two medically similar patients with relapsed large B-cell lymphoma (LBCL) can end up on completely different treatment paths, not because the biology differs, but because one lives near a cellular therapy center and the other lives two and a half hours away. Caregiver availability, lodging, and insurance authorization frequently decide which medically appropriate option is actually usable.

Consider an illustrative composite case (fictional, not published patient data): a 68-year-old man with diffuse large B-cell lymphoma who achieved a complete response to frontline chemoimmunotherapy, relapsed fourteen months after treatment, and then progressed on platinum-based salvage therapy. He is symptomatic but has no organ failure. Medically, he has several reasonable paths: CAR T-cell therapy, a CD20xCD3 bispecific antibody, another systemic regimen, a clinical trial, or goal-directed supportive care. The rest of his history changes which of those paths is realistic. He lives fifty-five minutes from his community oncologist and two hours and thirty-five minutes from the nearest cellular therapy center. His spouse is his only caregiver and works full time. No lodging benefit has been confirmed. His Medicare Advantage plan does not include the treatment center in network, and authorization has not yet started. None of these facts alone makes him ineligible for CAR T-cell therapy, but together they determine whether he is even referred, or accepts the referral if offered.

Why the Access History Matters as Much as the Treatment History

Community practice increasingly calls for taking a detailed access history alongside the standard treatment history. The treatment history establishes what might work; the access history establishes what would actually happen. Useful questions include how far the patient lives from both the local clinic and the treatment center under consideration, who will drive the patient, who will stay with the patient during required monitoring, where the patient will stay if travel is involved, and who owns insurance authorization if the treatment center sits outside the payer's network. Comparing treatment efficacy only makes sense after accounting for the operational burden attached to each medically appropriate option.

Five Operational Pathways for Relapsed or Refractory LBCL

Refractory lymphoma decisions tend to fall into five operational pathways, each carrying a distinct logistical footprint. A chemo-sensitive late relapse may still follow salvage chemotherapy and autologous transplant. [2] CAR T-cell therapy requires close monitoring and remaining near a healthcare facility for at least two weeks under current axi-cel and liso-cel labeling. [3, 4] An off-the-shelf bispecific antibody involves step-up dosing, recurring visits whose location depends on local capabilities, and a cytokine release syndrome (CRS) monitoring plan. [5, 6] Other systemic regimens, including treatment used as bridging therapy, depend on local infrastructure and how many cumulative visits a patient can realistically manage. A clinical trial may offer another pathway; goal-concordant supportive care remains appropriate when eligibility, expected benefit, and the patient's explicit goals point that way. These pathways are not interchangeable, and they do not all belong at the same line of therapy; the point is that efficacy comparisons only mean something once the operational burden of each option is on the table.

The Missing Denominator: What Published Efficacy Doesn't Show

Real-world outcomes depend heavily on which denominator a given study uses. In one retrospective analysis from a large academic cellular therapy service, 400 patients with hematologic malignancies were referred for CAR T-cell therapy evaluation, and 177 (44%) ultimately did not receive it. Among the 70 non-Hodgkin lymphoma patients who did not receive CAR T-cell therapy, 19 (27%) did not receive it because of rapid disease progression and 5 (7%) because of logistical reasons. These percentages describe NHL nonrecipients, not all NHL referrals. [1]

Studies beginning later in the treatment pathway answer a different question. Multicenter real-world cohorts of patients who actually reached infusion with standard-of-care CD19 CAR T-cell therapy for relapsed or refractory lymphoma have reported strong overall and complete response rates. [7] Real-world data on bispecific antibodies in this setting have similarly shown meaningful response rates among patients who were actually treated. [8] These are separate cohorts, not a single patient funnel or a head-to-head comparison. The difference in denominators is the point: response rates among treated patients do not capture referral-stage attrition, and community-level decision-making helps determine who ends up in that treated denominator in the first place.

Distance, Income, and Insurance Predict Who Actually Receives CAR T-Cell Therapy

The missing denominator is not random. Ahmed and colleagues analyzed Medicare fee-for-service and multipayer claims for patients with relapsed or refractory LBCL who had received at least two prior lines of therapy. A drive time of 121–240 minutes to the nearest treatment center, compared with 30 minutes or less, was associated with lower adjusted odds of receiving CAR T-cell therapy (adjusted odds ratio, 0.64). The lowest neighborhood-income group also had lower adjusted odds than the highest group (adjusted odds ratio, 0.44). Commercially insured patients were 1.5–3 times more likely to receive CAR T-cell therapy than patients with other payers in unadjusted analyses; payer was excluded from the adjusted model because it was collinear with age. [9] In a separate SEER-Medicare analysis, Chung and colleagues modeled a 37.6% relative increase in CAR T-cell use in poor-access states if average travel distance fell from 104.4 to 34.2 miles. This was a modeled estimate, not an observed nationwide increase. [10] These findings describe associations, not proof of causation. Distance, income, and insurance coverage are not administrative footnotes; they belong in the clinical assessment pathway while there is still time to modify the plan.

When a Drug Decision Becomes a System Decision

Bispecific antibody labeling illustrates how a drug decision becomes a systems decision. Regulatory requirements around hospitalization and monitoring differ across agents and have been evolving: current epcoritamab labeling allows individualized inpatient or outpatient monitoring after the first full dose in patients with DLBCL, based on comorbidities and situational factors, while glofitamab labeling calls for hospitalization during and for 24 hours after the initial 2.5-mg step-up dose, with further admission requirements depending on prior CRS. [5,6] Outpatient epcoritamab administration has also been studied prospectively in EPCORE NHL-6. [11] Neither label currently mandates routine prophylactic tocilizumab, though individual centers may adopt that approach locally based on emerging data; that may be a reasonable protocol choice, not a universal labeling requirement, and it raises its own formulary and coverage questions. Required premedication and access to CRS rescue treatment remain separate considerations. [5, 6]

Executing any of these regimens safely also requires reliable drug access for CRS management, trained infusion nursing, and an aligned emergency department pathway with a named clinician available if a patient develops suspected CRS overnight. When a prophylactic dosing policy or monitoring requirement cannot be operationalized locally, that is a delivery system constraint, and naming it accurately, rather than treating it as a fixed biological requirement, is the first step toward solving it.

Toward a Regional Care Model

Rather than framing this as community versus academic care, the field is converging toward a regional operating model. The community clinic can identify relapse, obtain tissue, stage and stabilize the patient, begin the access assessment, and coordinate bridging therapy. The treatment center can confirm the chosen pathway and own acute, specialized toxicities such as CRS. The patient then returns to the community where they live, with the handoff already defined in advance.

The FDA removed Risk Evaluation and Mitigation Strategies (REMS) requirements for the affected autologous CAR T-cell therapies in June 2025, lowering federal administrative burden. [12] Current Yescarta (axi-cel) and Breyanzi (liso-cel) labeling still requires daily monitoring for at least the first seven days and proximity to a healthcare facility for at least two weeks, along with availability of two doses of tocilizumab before infusion. [3, 4] Removing REMS did not remove geography, caregiver needs, or the need for emergency readiness. What should change immediately in practice: send an access history alongside every referral, document drive time to both the community and treatment centers, identify the caregiver and backup driver, confirm lodging and who is paying for it, name the payer, network status, authorization owner, and escalation contact, and define who owns each phase of care between the community practice and the treatment center, and when the patient returns. With five operational pathways and numerous possible regimens available, treatment selection is not disease biology alone; it is disease biology multiplied by patient circumstances and the delivery environment around both. A regimen is not a plan until the patient can reach it, tolerate it, and complete it.

For Patients: What to Ask If You're Being Considered for Advanced Lymphoma Therapy

If you or a family member are being evaluated for CAR T-cell therapy or a bispecific antibody for relapsed lymphoma, being medically eligible is only part of the picture. Ask your care team directly how far you would need to travel, how long you would need to stay near the treatment center, and who will need to be with you during that time. Ask whether the treatment center is in your insurance network, and if not, who is responsible for starting the authorization process and how long that typically takes.

These are not side questions; they can determine whether a treatment that is medically right for you is also realistic for your life. If travel or caregiver support is a barrier, say so early. Your oncology team may be able to identify lodging assistance, coordinate bridging treatment closer to home, or plan a handoff back to your community clinic once the most intensive phase of care is complete.

Key Takeaways

  • Medical eligibility for CAR T-cell therapy or bispecific antibodies does not guarantee a patient will receive it; distance, caregiver support, lodging, and insurance authorization often determine the actual outcome.

  • Taking a structured access history, alongside the treatment history, helps identify logistical barriers early enough to address them.

  • Response rates reported among treated patients do not capture referral-stage attrition; some referred patients never reach infusion because of disease progression, logistical barriers, or other reasons. [1,7,8]

  • Longer drive time in a specified travel-time stratum and lower neighborhood income were associated with reduced odds of receiving CAR T-cell therapy in national claims data. [9]

  • A regional care model, where community clinics manage identification, staging, and bridging, and treatment centers manage the specialized therapy and its acute toxicities, may help close this gap.

References

1. Valtis YK, Chin K-K, Nemirovsky D, et al. Barriers to chimeric antigen receptor T-cell therapy. JAMA Oncol. 2025;11(7):781–784. doi:10.1001/jamaoncol.2025.1127

2. Epperla N, Kumar A, Abutalib SA, et al. ASTCT clinical practice recommendations for transplantation and cellular therapies in diffuse large B cell lymphoma. Transplant Cell Ther. 2023;29(9):548–555. doi:10.1016/j.jtct.2023.06.012 

3. YESCARTA (axicabtagene ciloleucel). US prescribing information. Sections 2 and 5. Accessed September 17, 2026. https://www.fda.gov/media/108377/download

4. BREYANZI (lisocabtagene maraleucel). US prescribing information. Sections 2 and 5. Accessed September 17, 2026. https://www.fda.gov/media/145711/download

5. EPKINLY (epcoritamab-bysp). US prescribing information. 2026; application 761324, supplement 010. Sections 2 and 5. Accessed September 17, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761324s010lbl.pdf

6. COLUMVI (glofitamab-gxbm). US prescribing information. Sections 2 and 5. Accessed September 17, 2026. https://www.gene.com/download/pdf/columvi_prescribing.pdf

7. Nastoupil LJ, Jain MD, Feng L, et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium. J Clin Oncol. 2020;38(27):3119–3128. doi:10.1200/JCO.19.02104

8. Brooks TR, Zabor EC, Bedelu YB, et al. Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab. Blood. 2025;146(18):2177–2188. doi:10.1182/blood.2025029117

9. Ahmed N, Sun F, Teigland C, et al. Chimeric antigen receptor T-cell access in patients with relapsed/refractory large B-cell lymphoma: association of access with social determinants of health and travel time to treatment centers. Transplant Cell Ther. 2024;30(7):714–725. doi:10.1016/j.jtct.2024.04.017

10. Chung AP, Shafrin JT, Vadgama S, et al. Inequalities in CAR T-cell therapy access for US patients with relapsed/refractory DLBCL: a SEER-Medicare data analysis. Blood Adv. 2025;9(18):4727–4735. doi:10.1182/bloodadvances.2024015634

11. Andorsky D, Lopez AT, Vaidya R, et al. Epcoritamab monotherapy as outpatient treatment for patients with relapsed/refractory diffuse large B-cell lymphoma: interim results from EPCORE NHL-6. Clin Lymphoma Myeloma Leuk. Published online February 19, 2026. doi:10.1016/j.clml.2026.02.006

12. US Food and Drug Administration. FDA eliminates Risk Evaluation and Mitigation Strategies (REMS) for autologous chimeric antigen receptor (CAR) T cell immunotherapies. Published June 27, 2025. Accessed Septmember 17, 2026. https://www.fda.gov/news-events/press-announcements/fda-eliminates-risk-evaluation-and-mitigation-strategies-rems-autologous-chimeric-antigen-receptor